Pharmaceutical care in osteoporosis in post-menopausal women
Abstract
Introduction: Osteoporosis is considered to be a serious public health issue that affects the majority of the female population. Osteoporosis is a disease characterized by the reduction of bone mass and the modification of the bone structure, leading to enhanced bone fragility and an increased susceptibility to fracturing.
Methods and objectives: A questionnaire was administered to 22 postmenopausal women who used the pharmacy to collect their osteoporosis drugs over a period of four months. The objectives were to determine the incidence of risk factors and to identify the drugs used, adherence to treatment and adverse effects. The analysis of this data will then determine the pharmacutical action
Conclusions: In this study, it was observed that the most common drugs were bisphosphonates; that adherence was good and that there was a low incidence of adverse effects. The pharmacist has a major role in improving patient knowledge of treatment and disease, preventing complications, optimizing adherence and recommending healthy lifestyle habits.
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Ficha Técnica denosumab (Prolia®). Consultado el 19 de noviembre. Disponible en: http://www.aemps.gob.es/
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Finalización de la revisión del balance beneficio-riesgo de ranelato de estroncio (?Osseor®, ?Protelos®): restricciones de uso. 21 de febrero de 2014. Disponible en: http://www.aemps.gob.es/
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Ranelato de estroncio (?Osseor®, ?Protelos®): la revisión europea concluye que el balance beneficio-riesgo es desfavorable. 10 de enero de 2014. Disponible en: http://www.aemps.gob.es/
Bauer DC. Calcium Supplements and Fracture Prevention. N Engl J Med. 2013; 369:1537-1543.
Cianferotti L, D'Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2013; 5(3):127-39.
Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Medicamentos. 2013. p. 1336 – 1337, 2156.
Consejo General de Colegios Oficiales de Farmacéuticos. Guía Rápida para los Servicios de Atención Farmacéutica al paciente con osteoporosis. 2012.
McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126(1):13-20.
Mesa MP, Guañabens N. Guía de buena práctica clínica en geriatría. Osteoporosis. Sociedad Española de Reumatología. 2004. p. 13-18.
Palacios S, de Villiers TJ, Nardone Fde C, Levine AB, Williams R, Hines T et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas. 2013; 76(1): 81-87.
Pisani P, Renna MD, Conversano F, Casciaro E, Muratore M, Quarta E, et al. Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World J Radiol. 2013; 5(11):398-410.
Rigueira AI, Zardin E, López I, Sánchez L. Expectativas del beneficio/riesgo de la ingesta de calcio en mujeres con tratamientos para osteoporosis de Asturias; estudio ASFARCAL. Nutr Hosp. 2013; 28(2):428-437.
Rodriguez Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, Faus MJ. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Primaria. 2008; 40(8): 413-8
Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: A systematic literatura review. Reumatol Clin. 2013; 9(1):42-52.
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Finalización de la revisión del balance beneficio-riesgo de ranelato de estroncio (?Osseor®, ?Protelos®): restricciones de uso. 21 de febrero de 2014. Disponible en: http://www.aemps.gob.es/
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Ranelato de estroncio (?Osseor®, ?Protelos®): la revisión europea concluye que el balance beneficio-riesgo es desfavorable. 10 de enero de 2014. Disponible en: http://www.aemps.gob.es/
Bauer DC. Calcium Supplements and Fracture Prevention. N Engl J Med. 2013; 369:1537-1543.
Cianferotti L, D'Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2013; 5(3):127-39.
Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Medicamentos. 2013. p. 1336 – 1337, 2156.
Consejo General de Colegios Oficiales de Farmacéuticos. Guía Rápida para los Servicios de Atención Farmacéutica al paciente con osteoporosis. 2012.
McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126(1):13-20.
Mesa MP, Guañabens N. Guía de buena práctica clínica en geriatría. Osteoporosis. Sociedad Española de Reumatología. 2004. p. 13-18.
Palacios S, de Villiers TJ, Nardone Fde C, Levine AB, Williams R, Hines T et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas. 2013; 76(1): 81-87.
Pisani P, Renna MD, Conversano F, Casciaro E, Muratore M, Quarta E, et al. Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World J Radiol. 2013; 5(11):398-410.
Rigueira AI, Zardin E, López I, Sánchez L. Expectativas del beneficio/riesgo de la ingesta de calcio en mujeres con tratamientos para osteoporosis de Asturias; estudio ASFARCAL. Nutr Hosp. 2013; 28(2):428-437.
Rodriguez Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, Faus MJ. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Primaria. 2008; 40(8): 413-8
Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: A systematic literatura review. Reumatol Clin. 2013; 9(1):42-52.
Cartujo, B., & Aldasoro, P. (2016). Pharmaceutical care in osteoporosis in post-menopausal women. FarmaJournal, 1(1), 109–117. Retrieved from https://revistas.usal.es/cinco/index.php/2445-1355/article/view/13241
Most read articles by the same author(s)
- Andrea Gutierrez, Pilar Aldasoro, Therapeutic Approach to Urinary Tract Infections in the Community Pharmacy , FarmaJournal: Vol. 1 No. 2 (2016)
Similar Articles
- Estefanía Garcia, José Enrique Fuentes, Adherence and Treatment Compliance in Osteoporosis , FarmaJournal: Vol. 1 No. 2 (2016)
- Sandra Gomes Pereira, ASPECTS OF THE DEVELOPMENT OF NEW ANTI-LEISHMANIA DRUGS: FROM CONTROL OF NEGLECTED INFECTIONS TO PARASITE-HOST INTERACTIONS AND DRUG-RESISTANT PARASITES , FarmaJournal: Vol. 5 No. 1 (2020)
- Pedro Gómez, María Asunción González, Aníbal Martín, Juan José Ortiz De Urbina, “Efficacy and safety of eltrombopag as thromboyetic agent in the treatment of immune thrombocytopenic purpura in patients that started treatment at Complejo Asistencial Universitario de León during the period 2012-2015 , FarmaJournal: Vol. 2 No. 2 (2017)
- Antonio Sanz Diaz, Leticia Gómez De Segura Iriarte, EFECTIVENESS, SAFETY AND ACCEPTABILITY OF TERIFLUNOMIDE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS WHO STARTED TREATMENT AT HOSPITAL UNIVERISTARIO CENTRAL DE ASTURIAS (OVIEDO) IN 2015. , FarmaJournal: Vol. 2 No. 2 (2017)
- Lucía Fernandez, Javier Muñoz, Pharmaceutical care in ARMD (Age-related macular degeneration) , FarmaJournal: Vol. 1 No. 1 (2016)
- Irene Ferreras, José Enrique Fuentes, Pharmaceutical Intervention in Blood-Hypertension Control in a Community Pharmacy , FarmaJournal: Vol. 1 No. 2 (2016)
- Laura Pérez-Sánchez, Alfredo Ginés Casanova, Ana Isabel Morales, Nephrotoxicity biomarkers able to identify oncological patients at risk of developing kidney damage , FarmaJournal: Vol. 4 No. 2 (2019)
- Sergio A. Castrillejo, Julio López Abán, Claudio J. Salomon, Marta Pastor Navarro, José Luis Pedraz, Antonio Muro, Evaluation of new formulations of antihelmintic drugs for the treatment of schistosomiasis , FarmaJournal: Vol. 2 No. 2 (2017)
- Ana María Blanco Sánchez, Lucía Velasco Roces, EFFECTIVENESS SAFETY AND ACCEPTABILITY OF DIMETHYL FUMARATE FOR RELAPSING MULTIPLE SCLEROSIS IN PATIENTS WHOSE TREATMENT STARTED DURING 2015 IN THE HOSPITAL UNIVERITARIO CENTRAL DE ATURIAS , FarmaJournal: Vol. 2 No. 2 (2017)
- Javier González, Javier Tascón, Alfredo G. Casanova, Laura Vicente-Vicente, Ana I. Morales, Marta Prieto, Prediction of Immune Checkpoint Inhibitors-Associated Renal Damage in Oncology Patients , FarmaJournal: Vol. 9 No. 2 (2024)
You may also start an advanced similarity search for this article.
Downloads
Download data is not yet available.
+
−